Corcept Therapeutics executive sells over $140k in stock By Investing.com
Corcept Therapeutics executive sells over $140k in stock…
21,455€
1,39%
Echtzeit-Aktienkurs Corcept Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Corcept Therapeutics Inc. Aktie
Corcept Therapeutics director sells shares worth over $55k By Investing.com
Corcept Therapeutics director sells shares worth over $55k…
Corcept Therapeutics executive sells over $430k in stock By Investing.com
Corcept Therapeutics executive sells over $430k in stock…
Corcept Therapeutics Stock Is Down 27%. It’s an ‘Ideal Buying Opportunity.’
…
Corcept Therapeutics shares sink after losing patent infringement lawsuit against Teva
Corcept Therapeutics shares fell by more than a quarter on Tuesday morning after a court found against it in a patent…
The Zacks Analyst Blog Highlights Pfizer, Allogene Therapeutics and Corcept Therapeutics
Pfizer, Allogene Therapeutics and Corcept Therapeutics are included in this Analyst Blog.…
Corcept Therapeutics plunges amid patent trial with Teva (update)
…
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates
Corcept (CORT) delivered earnings and revenue surprises of 66.67% and 7.30%, respectively, for the quarter ended June 2023. Do the…
Insiderhandel: Chief Accounting Officer verkauft Aktien von Corcept Therapeutics im Wert von 236.000$
Lyon, Joseph Douglas - Vorstand - Tag der Transaktion: 2023-06-06...…
Form 8-K CORCEPT THERAPEUTICS For: May 19
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Insiderhandel: Chief Business Officer verkauft Aktien von Corcept Therapeutics im Wert von 716.100$
Robb, Gary Charles - Vorstand - Tag der Transaktion: 2023-05-09...…
Insiderhandel: Chief Business Officer verkauft Aktien von Corcept Therapeutics im Wert von 336.980$
Robb, Gary Charles - Vorstand - Tag der Transaktion: 2023-05-10...…
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
MENLO PARK, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged…
Corcept Therapeutics Announces Final Results of Tender Offer
MENLO PARK, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged…
Corcept Therapeutics Initiates CATALYST Clinical Trial
MENLO PARK, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged…
Corcept Therapeutics Shares Up About 9% on Tender Offer
Corcept Therapeutics Shares Up About 9% on Tender Offer...…
Corcept Therapeutics gains 10% on share buyback program
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Corcept Therapeutics (CORT) Lags Q4 Earnings and Revenue Estimates
Corcept (CORT) delivered earnings and revenue surprises of -39.13% and 0.66%, respectively, for the quarter ended December 2022. Do the…
Corcept Therapeutics GAAP EPS of $0.15 misses by $0.08, revenue of $103M misses by $2.08M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 10-K CORCEPT THERAPEUTICS For: Dec 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation - CORT
New York, New York--(Newsfile Corp. - January 1, 2023) - WHY: Rosen Law Firm, a global investor rights law firm,…
NATIONALLY RANKED ROSEN LAW FIRM Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation - CORT
NEW YORK, Dec. 30, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation…
Form 8-K CORCEPT THERAPEUTICS For: Dec 08
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals
MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged…
Insiderhandel: Chief Business Officer verkauft Aktien von Corcept Therapeutics im Wert von 125.308$
Robb, Gary Charles - Vorstand - Tag der Transaktion: 2022-11-22...…
Insiderhandel: Chief Business Officer verkauft Aktien von Corcept Therapeutics im Wert von 4.842$
Robb, Gary Charles - Vorstand - Tag der Transaktion: 2022-11-23...…
Corcept Therapeutics (CORT) Tops Q3 Earnings Estimates
Corcept (CORT) delivered earnings and revenue surprises of 30.43% and 5.57%, respectively, for the quarter ended September 2022. Do the…
Corcept Therapeutics GAAP EPS of $0.30, revenue of $101.7M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
MENLO PARK, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged…
Corcept Therapeutics Q3 2022 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Corcept Therapeutics starts phase 2 trial of its ALS treatment
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)
MENLO PARK, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged…